These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 17035418)
1. Pulmonary hypertension trials: current end points are flawed, but what are the alternatives? Roberts K; Preston I; Hill NS Chest; 2006 Oct; 130(4):934-6. PubMed ID: 17035418 [No Abstract] [Full Text] [Related]
2. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621 [TBL] [Abstract][Full Text] [Related]
3. Up-front combination therapy in pulmonary arterial hypertension: from clinical trials to 'real world' observational studies. Grignola JC Int J Cardiol; 2014 May; 173(3):349-50. PubMed ID: 24698227 [TBL] [Abstract][Full Text] [Related]
4. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. Frost AE; Quiñones MA; Zoghbi WA; Noon GP J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478 [TBL] [Abstract][Full Text] [Related]
8. The globalization of clinical trials in pulmonary arterial hypertension. Park MH; Rubin LJ J Heart Lung Transplant; 2010 Feb; 29(2):157-8. PubMed ID: 20113908 [No Abstract] [Full Text] [Related]
9. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Horn EM; Barst RJ; Poon M Chest; 2000 Oct; 118(4):1229-30. PubMed ID: 11035709 [No Abstract] [Full Text] [Related]
10. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension. Stricker H; Domenighetti G; Fiori G; Mombelli G Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827 [TBL] [Abstract][Full Text] [Related]
11. Low-dose epoprostenol improved pulmonary hypertension in a patient with systemic lupus erythematosus. Matsukawa Y; Igei K; Nozaki T; Ohki T; Shimizu T; Kitamura N; Mitamura K; Takei M; Kasamaki Y; Sawada S Clin Rheumatol; 2007 Apr; 26(4):582-3. PubMed ID: 16391888 [TBL] [Abstract][Full Text] [Related]
12. A 50-year-old woman with dyspnea, lower extremity edema, and volume loss of the right hemithorax. Shostak E; Sarwar A Chest; 2009 Aug; 136(2):628-632. PubMed ID: 19666764 [No Abstract] [Full Text] [Related]
13. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension]. Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363 [No Abstract] [Full Text] [Related]
14. [Pulmonary artery hypertension: when life hangs by a thread]. Houde J Perspect Infirm; 2010; 7(3):22-6. PubMed ID: 21744581 [No Abstract] [Full Text] [Related]
18. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Chin KM; Badesch DB; Robbins IM; Tapson VF; Palevsky HI; Kim NH; Kawut SM; Frost A; Benton WW; Lemarie JC; Bodin F; Rubin LJ; McLaughlin V Am Heart J; 2014 Feb; 167(2):218-225.e1. PubMed ID: 24439983 [TBL] [Abstract][Full Text] [Related]
19. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982 [TBL] [Abstract][Full Text] [Related]
20. Treatment of pulmonary hypertension with inhaled agents in the pediatric intensive care unit. Gillis HC; Fischer G; Gupta S Am J Health Syst Pharm; 2018 Feb; 75(4):171-172. PubMed ID: 29436464 [No Abstract] [Full Text] [Related] [Next] [New Search]